HOV-12020 (Palm tocotrienols complex)

Phase 2Small molecule

HOV-12020 (Palm tocotrienols complex) is one of 6 small molecule programs targeting CADASIL. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CADASILActive, not recruiting

CADASILPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in CADASIL

#DrugCompanyPhaseTrials

Pletal

Pradaxa

1 3

Cerebrolysin

EEver Neuro Pharma GmbH

Phase 2

1 4

Antiplatelets

Pfizer

Phase 2

1 5

Adrenomedullin

DDanish Headache Center

Phase 2

1 6

HOV-12020 (Palm tocotrienols complex)

HHovid Berhad

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

CADASIL1 trial

Efficacy and Safety of Tocotrienols in CADASIL

Completed·HHovid Berhad·Phase 2·NCT04658823·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HOV-12020 (Palm tocotrienols complex). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HOV-12020 (Palm tocotrienols complex) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HOV-12020 (Palm tocotrienols complex). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hovid Berhad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHovid Berhad

HOV-12020 (Palm tocotrienols complex)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

CADASIL1 trial

References

Drug Info

Quick Facts

Related News